News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Market source Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Foghorn Therapeutics (NASDAQ:FHTX) recently released strong second-quarter results, with revenue exceeding expectations by 103% and a smaller-than-predicted loss per share. Following these positive results, analysts have significantly upgraded their revenue and reduced their loss estimates for 2026. Despite the upgrades, the consensus price target …
Wall Street analysts project an 88.5% upside for Foghorn Therapeutics (FHTX), with a mean price target of $11.44. Despite potential skepticism regarding price targets, strong agreement among analysts and a positive trend in earnings estimate revisions suggest a solid upside potential for the stock. …
Foghorn Therapeutics Inc. (NASDAQ:FHTX) has received a "Moderate Buy" consensus rating from eight analysts, with an average 12-month price target of $11.43, significantly higher than its $6.07 opening price. The company recently surpassed quarterly expectations, reporting a smaller loss per share and higher revenue …
Wall Street Zen has upgraded Foghorn Therapeutics (NASDAQ:FHTX) from a "sell" to a "hold" rating, while Weiss Ratings maintained a "sell." Despite this, MarketBeat's consensus remains a "Moderate Buy" with a target of $11.43. The company's stock rose 9% to $6.07 after reporting a …
H.C. Wainwright has reiterated its Buy rating for Foghorn Therapeutics (FHTX.US) and maintained its price target at $13. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Foghorn Therapeutics announced its Q2 2026 results, detailing advancements in its oncology and immunology pipeline, including progress in its SMARCA2 inhibitor Phase 1 trial and several preclinical degrader programs. The company maintains a strong financial position with $168 million in cash, extending its runway …
Foghorn Therapeutics Inc. reported its 2026 quarterly results, showing a significant increase in revenue to $16.07M and a narrowed net loss of ($7.19M), leading to a diluted loss per share of ($0.1). The improved financial performance was largely driven by a collaboration with Lilly …
Foghorn Therapeutics Inc. (FHTX) reported a Q2 loss of $0.1 per share, outperforming the Zacks Consensus Estimate of a $0.23 loss, and significantly beat revenue estimates with $16.07 million against an expected $8.12 million. Despite this, the company's shares have declined by 9.6% year-to-date, …
Foghorn Therapeutics (Nasdaq: FHTX) released its second-quarter 2026 financial and corporate update, highlighting the advancement of its FHD-909 Phase 1 trial for NSCLC and its wholly-owned pipeline including selective EP300 and CBP degraders. The company also announced a novel oral small molecule in immunology …
Foghorn Therapeutics reported Q2 2026 collaboration revenue of $16.1 million and narrowed its net loss to $7.2 million, supported by decreased R&D and G&A expenses. The company's FHD-909 lung cancer trial is progressing, with IND filings targeted for 2027 for a selective EP300 degrader …
Foghorn Therapeutics (FHTX) reported significantly narrowed net losses and increased collaboration revenue in Q2 2026, primarily due to a $14.2 million cumulative catch-up adjustment from its Eli Lilly collaboration. The company's net loss decreased to $7.2 million from $17.9 million year-over-year, and revenue rose …
Foghorn Therapeutics Inc (FHTX) is projected to report a loss of 26 cents per share, according to a preview from Refinitiv. This earnings forecast provides an outlook on the company's financial performance.
This article provides financial data for Foghorn Therapeutics Inc. (NASDAQ: FHTX), specifically its price-to-earnings forward metric. It originates from TradingView and indicates that the market was closed at the time of publication, with no trades reported. The content is presented as a financial snapshot …
The article discusses Foghorn Therapeutics Inc. (FHTX) and its revenue breakdown by business segments and regional contributions. However, it explicitly states that relevant data for these categories have not yet been disclosed by the company. The page provides basic stock information for FHTX, including …
This article details the shareholder structure of Foghorn Therapeutics Inc. (FHTX), listing its major shareholders and their respective proportions. It also presents institutional shareholding data over several quarters and outlines FHTX's presence in various ETFs.
This article provides a comprehensive stock analysis of Foghorn Therapeutics Inc. (FHTX) from TradingKey, noting its stable fundamentals, significant growth potential, and "fairly valued" status in the Biotechnology & Medical Research industry. The company has a high institutional ownership, strong buy ratings from multiple …
This article provides a detailed cash flow statement for Foghorn Therapeutics Inc. (FHTX), covering quarterly and annual data for operating, investing, and financing activities. It includes key financial metrics like net income, capital expenditures, and free cash flow, along with an overview of the …
This article focuses on the enterprise value to revenue forward metric for Foghorn Therapeutics Inc. (NASDAQ: FHTX). It presents this financial data point within the context of the company's stock information on the Nasdaq Stock Market. The content appears to be a stub or …
This article provides a detailed quarterly income statement for Foghorn Therapeutics Inc. (FHTX), presenting financial data such as total revenue, operating expenses, operating profit, and net income over several fiscal quarters. It also includes an FAQ section explaining how to read an income statement, …
This article provides details on Foghorn Therapeutics Inc.'s (FHTX) institutional confidence score and shareholding data. The company has a current institutional shareholding score of 7.00, ranking 80th in its industry, with institutional shareholding at 72.78%, a slight decrease quarter over quarter. The largest institutional …
The article analyzes Foghorn Therapeutics Inc. (NASDAQ: FHTX) using algorithmic frameworks, noting conflicting sentiment across horizons and a mid-channel oscillation pattern. It presents three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, and highlights a 50.5:1 risk-reward short setup.
Search by ticker symbol or company name and select a result to open its chart.